Daclatasvir Tablets
Developed to target hepatitis C virus; indicated to alleviate viral load and support liver health.
Strengths: 60mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Daklinza
- Therapeutic class
Direct-Acting Antiviral
- Pharmacological class
NS5A Inhibitor
- Contraindications
hypersensitivity to active ingredient
- Minor side effects
headache; fatigue; nausea
- Moderate side effects
anaemia; diarrhoea
- Serious side effects
severe bradycardia — requires immediate medical attention
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Bristol-Myers Squibb
- Onset Time
rapid viral decline
- Duration
12–24 weeks
- Storage instructions
Store below 30°C.
- Drug interactions
amiodarone; carbamazepine; st. john's wort
- Age restrictions
Not recommended for children under 18.
- Pregnancy and breastfeeding
Pregnancy: use only if benefits outweigh risks. Breastfeeding: caution advised.
Patient summary
Developed to target hepatitis C virus; indicated to alleviate viral load and support liver health.
Mechanism of action
An NS5A replication complex inhibitor. It binds to the NS5A protein of the hepatitis C virus, blocking the viral replication cycle and preventing the assembly of new virions.
Daclatasvir Tablets
Developed to target hepatitis C virus; indicated to alleviate viral load and support liver health.
Editorial Notes
- Active ingredient(s): Daclatasvir
- Listed indication(s): Chronic Hepatitis C
Available option
- 28 tablets - 60 mg1364-60-mg-16386